期刊
GENE THERAPY
卷 17, 期 1, 页码 72-82出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/gt.2009.112
关键词
DNA vaccines; immune responses; molecular adjuvants; immune modulation
类别
资金
- National Institutes of Health through NIAIDS [F32AI054152]
- NIH-NIAID-HIVRAD
- [N01A1154 NIAIDS-HVDDT]
- [T32-A107632]
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI054152] Funding Source: NIH RePORTER
A hurdle facing DNA vaccine development is the ability to generate strong immune responses systemically and at local immune sites. We report a novel systemically administered DNA vaccination strategy using intramuscular codelivery of CCL27 or CCL28, which elicited elevated peripheral IFN-gamma and antigen-specific IgG while driving antigen-specific T-cell secretion of cytokine and antibody production in the gut-associated lymphoid tissue and lung. This strategy resulted in induction of long-lived antibody responses that neutralized influenza A/PR8/34 and protected mice from morbidity and mortality associated with a lethal intranasal viral challenge. This is the first example of the use of CCL27 and CCL28 chemokines as adjuvants to influence a DNA vaccine strategy, suggesting further examination of this approach for manipulation of vaccine-induced immunity impacting both quality and phenotype of responses. Gene Therapy (2010) 17, 72-82; doi: 10.1038/gt.2009.112; published online 22 October 2009
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据